<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951936</url>
  </required_header>
  <id_info>
    <org_study_id>A1 version 2</org_study_id>
    <nct_id>NCT02951936</nct_id>
  </id_info>
  <brief_title>The Utility of Regional Bioimpedance in Chronically Ventilated Patients</brief_title>
  <official_title>The Utility of Regional Bioimpedance in Chronically Ventilated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronically ventilated patients will be hemodynamically measured by bioimpedance (NiCAS by NI&#xD;
      medical ltd.) for cardiac output, Total peripheral resistance and other NICAS derived&#xD;
      parameters.&#xD;
&#xD;
      Patients fluid balance will be planned according to these parameters and the rate of&#xD;
      liberation from ventilator and rate of worsening renal function will be measured&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be divided into two groups , the study group and the control group randomly&#xD;
      assigned by a computer program .&#xD;
&#xD;
      After obtaining written informed consent , cardiac monitoring will be carried out by means of&#xD;
      a NiCAS patients in both groups.The physician will not be exposed to the measurement data of&#xD;
      the patients in the control group. For the research group : Monitoring will be carried out&#xD;
      once a day , preferably at the same time the first three days . An increase in time interval&#xD;
      is possible in accordance with an improvement in the patient . Patients will be treated&#xD;
      according to the protocol described in Figure 1. Also , a graphic description of the various&#xD;
      treatment zones and the exclusion zone is presented in Figure 2 .&#xD;
&#xD;
      For the control group patients will be treated according to the usual ward protocols.&#xD;
&#xD;
      The basic rules are:&#xD;
&#xD;
      Avoiding over- drying by using parameter TBW .&#xD;
&#xD;
        -  Avoidance of renal dysfunction by maintaining the cardiac output above 2.3 , and&#xD;
           avoiding the use of beta-blocker overdose in cases of low cardiac output and bradycardia&#xD;
           as a result of maintaining an average blood pressure over 70 .&#xD;
&#xD;
        -  In cases of high peripheral resistance - Reduction of resistance while maintaining&#xD;
           normal blood pressure .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulties in recrutment&#xD;
  </why_stopped>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of days ventilated</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>90 days</time_frame>
    <description>will be assessed by blood test as Creatinin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>NiCAS treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure each patient with the NiCAS once a day If Cardiac Index &lt; 2.9 +Total Peripheral resistance Index &gt;3000+Mean arterial pressure &gt;70mmHG then add vasodilators.&#xD;
If Heart Rate&lt;60 consider to reduce beta blockers dose If Cardiac Index&gt;4.2 and Mean arterial pressure 70-100mmHG and HR &gt;100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non NiCAS treated</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NiCAS treated</intervention_name>
    <description>Measure each patient with the NiCAS once a day If Cardiac Index &lt; 2.9 +Total Peripheral resistance Index &gt;3000+Mean arterial pressure &gt;70mmHG then add vasodilators.&#xD;
If Heart Rate&lt;60 consider to reduce beta blockers dose If Cardiac Index&gt;4.2 and Mean arterial pressure 70-100mmHG and HR &gt;100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics</description>
    <arm_group_label>NiCAS treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non NiCAS treated</intervention_name>
    <description>Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care</description>
    <arm_group_label>Non NiCAS treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All chronically ventilated patients (ventilated for more than 14 days)&#xD;
&#xD;
          -  Age between 18-90&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non ventilated patient&#xD;
&#xD;
          -  Total body water &gt;80%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>September 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>February 11, 2018</last_update_submitted>
  <last_update_submitted_qc>February 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Pierre Singer</investigator_full_name>
    <investigator_title>Director of ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

